Bayer's 84% Rally Flashes a Technical Warning — A Supreme Court Win and $7.25 Billion Hearing Will Determine the Next Leg
Veröffentlicht: 29.06.2026 um 10:52 Uhr, Redaktion boerse-global.de
The euphoria is palpable, but the charts are screaming caution. After the US Supreme Court handed Bayer a landmark legal victory on June 26, the stock ripped 24% higher in seven trading days, pushing the 12-month gain to 84%. By Monday, June 29, the shares sat at €47.16 — barely 5.5% below the 52-week high of €49.93. Yet the RSI had climbed to 81.3, deep in overbought territory, and a classic shooting-star candlestick pattern had formed that day. Chartists see it as the kind of warning signal that often follows a steep, euphoric rally.
Friday’s close of €46.61 had already reflected a 22.63% weekly surge, and the 30-day gain was approaching 30%. But the speed of the advance has left the stock vulnerable to a pullback. The question now is whether the legal relief is enough to sustain the momentum — or whether the next catalyst will come from a Missouri courtroom on July 9.
A Historic Ruling, but Not a Clean Slate
The Supreme Court’s 7-2 decision, handed down in the Durnell case, holds that federal law preempts most state-level failure-to-warn claims on glyphosate products. The ruling effectively neutralises roughly 100,000 pending lawsuits, giving Bayer a legal shield it has lacked for years. The opinion was issued on June 26, following the court’s decision in the Durnell case a day earlier. For the first time in a long while, the company can begin to price in less legal uncertainty.
But the victory is not absolute. The preemption applies only to failure-to-warn claims; other types of liability remain. And Senator Cory Booker has already introduced the No Immunity for Glyphosate Act, an amendment to the Farm Bill that would restore manufacturer liability under both federal and state law if glyphosate is found to be carcinogenic. Whether the bill gains the necessary political traction is uncertain, but it injects a fresh dose of policy risk into what had looked like a clean win.
Should investors sell immediately? Or is it worth buying Bayer?
The Bull Case: Pipeline Spending and a Leaner Structure
With less litigation weighing on the balance sheet, management can redirect resources to operations and growth. CEO Bill Anderson has signalled openness to structural change, though no formal breakup is planned. A new organisational model is expected to deliver €2 billion in annual savings from 2026 onward, and the agriculture division CropScience is already showing margin improvement.
The real story, however, sits in the pharma pipeline. The Phase III OCEANIC-STROKE trial of Asundexian — an oral factor XIa inhibitor — demonstrated a 26% reduction in stroke risk among high-risk patients with no increase in bleeding. The data were published in the New England Journal of Medicine in April 2026. If approved, Asundexian could become a meaningful growth driver, complementing a pharma division that targets mid-single-digit growth from 2027 and an operating margin of around 30% by 2030.
The Bear Case: Debt, Cash Burn, and Political Clouds
Those ambitions face a wall of financial pressure. Net financial debt stands at roughly €33 billion, and the company expects to spend around €5 billion on litigation settlements and legal costs this year alone. Free cash flow is projected to be negative by as much as €2.5 billion. The Supreme Court ruling may cap future liabilities, but it does nothing to erase the cash already committed or the drag from existing obligations.
Regulatory headwinds add another layer. Stricter scrutiny of drug pricing in the US could squeeze margins in Bayer’s pharma business. The RSI, which stood at 80.6 as of Friday, suggests the stock is technically stretched. Profit-taking after such a rapid run looks likely, and the annualised 30-day volatility of 57.79% reminds investors that sharp swings are the norm, not the exception.
The July 9 Date That Will Set the Tone
All eyes now turn to St. Louis, where on July 9 a fairness hearing will consider final approval of a class settlement worth $7.25 billion. The deal is designed to cover both current and future glyphosate claims. A favourable ruling would cement the legal progress and give Bayer a stable foundation to focus on debt reduction and pipeline execution. A delay or rejection would reopen the liability fears that have haunted the stock for years, potentially triggering a sharp sell-off.
Bayer at a turning point? This analysis reveals what investors need to know now.
Technical Levels and What Comes Next
For now, the stock remains well above its key moving averages. The 200-day sits at €36.68, the 50-day at €38.05, and the 100-day at €39.58. As long as the share price holds above those levels, the medium-term picture stays constructive. A sustained break above the €49.93 high would open further upside. But the first support lies around €39.58, which would represent a roughly 16% pullback from Monday’s close — a correction, not a crash, but a sobering one after the heady gains of the past week.
The Supreme Court gave Bayer the legal clarity it desperately needed. The next two weeks will show whether the market can stomach the political and financial risks that remain.
Ad
Bayer Stock: New Analysis - 29 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
